SG10201802444XA - Primary carboxamides as btk inhibitors - Google Patents

Primary carboxamides as btk inhibitors

Info

Publication number
SG10201802444XA
SG10201802444XA SG10201802444XA SG10201802444XA SG10201802444XA SG 10201802444X A SG10201802444X A SG 10201802444XA SG 10201802444X A SG10201802444X A SG 10201802444XA SG 10201802444X A SG10201802444X A SG 10201802444XA SG 10201802444X A SG10201802444X A SG 10201802444XA
Authority
SG
Singapore
Prior art keywords
btk inhibitors
primary carboxamides
carboxamides
primary
btk
Prior art date
Application number
SG10201802444XA
Other languages
English (en)
Inventor
Dominique Bonafoux
Heather Davis
Kristine Frank
Michael Friedman
J Herold
Michael Hoemann
Raymond Huntley
Augustine OSUMA
George SHEPPARD
Gagandeep Somal
Camp Jennifer Van
Epps Stacy Van
Anil Vasudevan
Grier Wallace
Lu Wang
Zhi Wang
Noel Wilson
Xiangdong Xu
Original Assignee
Abbvie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Inc filed Critical Abbvie Inc
Publication of SG10201802444XA publication Critical patent/SG10201802444XA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/12—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Indole Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
SG10201802444XA 2013-06-26 2014-06-26 Primary carboxamides as btk inhibitors SG10201802444XA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361839729P 2013-06-26 2013-06-26
US201361897577P 2013-10-30 2013-10-30

Publications (1)

Publication Number Publication Date
SG10201802444XA true SG10201802444XA (en) 2018-05-30

Family

ID=52116191

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201802444XA SG10201802444XA (en) 2013-06-26 2014-06-26 Primary carboxamides as btk inhibitors
SG11201510503UA SG11201510503UA (en) 2013-06-26 2014-06-26 Primary carboxamides as btk inhibitors

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG11201510503UA SG11201510503UA (en) 2013-06-26 2014-06-26 Primary carboxamides as btk inhibitors

Country Status (28)

Country Link
US (4) US9567339B2 (enExample)
EP (3) EP4008328A1 (enExample)
JP (3) JP6509838B2 (enExample)
KR (1) KR102273997B1 (enExample)
CN (1) CN105530932B (enExample)
AU (3) AU2014302365B2 (enExample)
BR (1) BR112015032330B1 (enExample)
CA (1) CA2916298C (enExample)
CY (1) CY1121146T1 (enExample)
DK (1) DK3013337T3 (enExample)
ES (1) ES2708998T3 (enExample)
HR (1) HRP20190093T1 (enExample)
HU (1) HUE040645T2 (enExample)
IL (2) IL243332B (enExample)
LT (1) LT3013337T (enExample)
ME (1) ME03307B (enExample)
MX (1) MX355943B (enExample)
NZ (1) NZ754039A (enExample)
PL (1) PL3013337T3 (enExample)
PT (1) PT3013337T (enExample)
RS (1) RS58273B1 (enExample)
RU (1) RU2708395C2 (enExample)
SG (2) SG10201802444XA (enExample)
SI (1) SI3013337T1 (enExample)
TW (1) TWI642657B (enExample)
UY (1) UY35630A (enExample)
WO (1) WO2014210255A1 (enExample)
ZA (1) ZA201509012B (enExample)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY35464A (es) 2013-03-15 2014-10-31 Araxes Pharma Llc Inhibidores covalentes de kras g12c.
CA2916298C (en) * 2013-06-26 2021-10-12 Abbvie Inc. Primary carboxamides as btk inhibitors
US9951056B2 (en) 2013-09-30 2018-04-24 Beijing Innocare Pharma Tech Co., Ltd. Substituted nicotinamide inhibitors of BTK and their preparation and use in the treatment of cancer, inflammation and autoimmune disease
TWI659021B (zh) 2013-10-10 2019-05-11 亞瑞克西斯製藥公司 Ｋｒａｓ ｇ１２ｃ之抑制劑
PE20190710A1 (es) * 2014-10-24 2019-05-17 Bristol Myers Squibb Co Compuestos de indol carboxamida utiles como inhibidores de cinasas
AR104259A1 (es) * 2015-04-15 2017-07-05 Celgene Quanticel Res Inc Inhibidores de bromodominio
US10253041B2 (en) * 2015-07-27 2019-04-09 Eli Lilly And Company 7-phenylethylamino-4H-pyrimido[4,5-d][1,3]oxazin-2-one compounds and their use as mutant IDH1 inhibitors
MA52119A (fr) 2015-10-19 2018-08-29 Ncyte Corp Composés hétérocycliques utilisés comme immunomodulateurs
HRP20231547T1 (hr) * 2015-11-17 2024-03-15 Merck Patent Gmbh Postupci liječenja multiple skleroze primjenom spojeva pirimidina i piridina s aktivnošću inhibicije btk
PT3377488T (pt) 2015-11-19 2022-11-21 Incyte Corp Compostos heterocíclicos como imunomoduladores
MX2021006804A (es) 2015-12-17 2023-01-13 Merck Patent Gmbh Antagonistas policiclicos del receptor 7/8 tipo toll (tlr7/8) y uso de los mismos en el tratamiento de trastornos inmunitarios.
SI3394033T1 (sl) 2015-12-22 2021-03-31 Incyte Corporation Heterociklične spojine kot imunomodulatorji
WO2017192961A1 (en) 2016-05-06 2017-11-09 Incyte Corporation Heterocyclic compounds as immunomodulators
US20170335530A1 (en) * 2016-05-23 2017-11-23 Fatu K. Kofa Pet waste vacuum and disposal device and method
EP3464279B1 (en) 2016-05-26 2021-11-24 Incyte Corporation Heterocyclic compounds as immunomodulators
CN105924840A (zh) * 2016-06-01 2016-09-07 扬州兰都塑料科技有限公司 一种阻燃电力电缆
CN105837993A (zh) * 2016-06-01 2016-08-10 扬州兰都塑料科技有限公司 一种阻燃电力电缆用阻燃剂
CN106083707B (zh) * 2016-06-01 2018-10-26 温州大学 一种非对称杂芳基硫醚的合成方法
CN105884673B (zh) * 2016-06-03 2018-05-11 温州大学 一种吲哚衍生物的合成方法
PL3472167T3 (pl) 2016-06-20 2022-12-19 Incyte Corporation Związki heterocykliczne jako immunomodulatory
EP3484866B1 (en) 2016-07-14 2022-09-07 Incyte Corporation Heterocyclic compounds as immunomodulators
RU2758686C2 (ru) 2016-08-08 2021-11-01 Мерк Патент Гмбх Антагонисты tlr7/8 и их применение
ES2941716T3 (es) 2016-08-29 2023-05-25 Incyte Corp Compuestos heterocíclicos como inmunomoduladores
LT3507282T (lt) * 2016-09-02 2021-01-25 Bristol-Myers Squibb Company Indolinių karboksamido junginių gamybos būdas
JP2019534266A (ja) 2016-10-14 2019-11-28 江蘇恒瑞医薬股▲ふん▼有限公司 ５員ヘテロアリール環の架橋した環誘導体、その製造方法およびその医学的使用
KR20190112263A (ko) 2016-12-12 2019-10-04 멀티비르 인코포레이티드 암 및 감염성 질환의 치료 및 예방을 위한 바이러스 유전자 치료요법 및 면역 체크포인트 억제제를 포함하는 방법 및 조성물
MY197501A (en) 2016-12-22 2023-06-19 Incyte Corp Tetrahydro imidazo[4,5-c]pyridine derivatives as pd-l1 internalization inducers
EP3558973B1 (en) 2016-12-22 2021-09-15 Incyte Corporation Pyridine derivatives as immunomodulators
WO2018119286A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Bicyclic heteroaromatic compounds as immunomodulators
KR102696516B1 (ko) 2016-12-22 2024-08-22 인사이트 코포레이션 면역조절제로서의 벤조옥사졸 유도체
US20180179201A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Heterocyclic compounds as immunomodulators
US20200385364A1 (en) * 2017-01-26 2020-12-10 Araxes Pharma Llc Fused n-heterocyclic compounds and methods of use thereof
US11358959B2 (en) 2017-01-26 2022-06-14 Araxes Pharma Llc Benzothiophene and benzothiazole compounds and methods of use thereof
CN106928201B (zh) * 2017-02-22 2019-08-23 江汉大学 合成2-乙烯基吲哚衍生物的方法
CN110831933A (zh) 2017-05-25 2020-02-21 亚瑞克西斯制药公司 喹唑啉衍生物作为突变kras、hras或nras的调节剂
CN107098845A (zh) * 2017-07-06 2017-08-29 贵州大学 一种5‑氰基‑6‑硝基吲哚的制备工艺
CN107721988A (zh) * 2017-10-31 2018-02-23 无锡福祈制药有限公司 具有抗炎活性的异吲哚‑1‑酮类化合物
US11100492B2 (en) 2018-02-19 2021-08-24 Peter Garrett General purpose re-loadable card aggregation implementation
EP4212529B1 (en) 2018-03-30 2025-01-29 Incyte Corporation Heterocyclic compounds as immunomodulators
FI4219492T3 (fi) 2018-05-11 2025-02-17 Incyte Corp Heterosyklisiä yhdisteitä immunomodulaattoreina
EP3829580A1 (en) 2018-08-01 2021-06-09 Araxes Pharma LLC Heterocyclic spiro compounds and methods of use thereof for the treatment of cancer
AU2020242287A1 (en) 2019-03-21 2021-09-02 INSERM (Institut National de la Santé et de la Recherche Médicale) A Dbait molecule in combination with kinase inhibitor for the treatment of cancer
CA3150434A1 (en) 2019-08-09 2021-02-18 Incyte Corporation Salts of a pd-1/pd-l1 inhibitor
AR120109A1 (es) 2019-09-30 2022-02-02 Incyte Corp Compuestos de pirido[3,2-d]pirimidina como inmunomoduladores
KR20220098759A (ko) 2019-11-08 2022-07-12 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 키나제 억제제에 대해 내성을 획득한 암의 치료 방법
IL292524A (en) 2019-11-11 2022-06-01 Incyte Corp Salts and crystalline forms of a pd-1/pd-l1 inhibitor
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
CN116710430A (zh) * 2020-05-12 2023-09-05 皮姆维制药公司 用于恢复突变p53功能的方法和化合物
WO2021247748A1 (en) * 2020-06-02 2021-12-09 Gb005, Inc. Kinase inhibitors
BR112022025692A2 (pt) 2020-06-19 2023-02-28 Bayer Ag 1,3,4-oxadiazóis e seus derivados como fungicidas
IL300087A (en) 2020-08-04 2023-03-01 Novartis Ag Treatment of CLL
CR20230185A (es) 2020-09-30 2023-06-27 Astrazeneca Ab Compuestos y su uso en el tratamiento del cáncer
US20230382900A1 (en) * 2020-10-30 2023-11-30 Newave Pharmaceutical Inc. Inhibitors of btk
WO2022099075A1 (en) 2020-11-06 2022-05-12 Incyte Corporation Crystalline form of a pd-1/pd-l1 inhibitor
US11780836B2 (en) 2020-11-06 2023-10-10 Incyte Corporation Process of preparing a PD-1/PD-L1 inhibitor
PE20231438A1 (es) 2020-11-06 2023-09-14 Incyte Corp Proceso para hacer un inhibidor de pd-1/pd-l1 y sales y formas cristalinas del mismo
WO2022155111A1 (en) * 2021-01-12 2022-07-21 Gb005, Inc. Indole derivatives as kinase inhibitors
CN114957242B (zh) * 2021-02-23 2023-08-22 药雅科技(上海)有限公司 吡啶并杂环类化合物作为激酶抑制剂的制备及其应用
CN114853723B (zh) * 2021-02-03 2023-11-24 药雅科技(上海)有限公司 吲哚类化合物btk抑制剂的制备及其应用
CN114957241B (zh) * 2021-02-23 2023-08-22 药雅科技(上海)有限公司 杂环类化合物作为激酶抑制剂的制备及其应用
WO2022166468A1 (zh) * 2021-02-03 2022-08-11 药雅科技(上海)有限公司 Bruton's酪氨酸激酶抑制剂及其应用
CN114853752B (zh) * 2021-02-03 2023-08-22 药雅科技(上海)有限公司 Btk抑制剂吡啶并杂环类化合物的制备及其应用
WO2022228302A1 (en) * 2021-04-25 2022-11-03 Bionova Pharmaceuticals (Shanghai) Limited Heteroaromatic carboxamide compounds and its use
CN115521313B (zh) * 2021-06-24 2023-11-03 山东大学 一种降解btk蛋白的化合物及其制备方法和应用
IL314122A (en) 2022-01-27 2024-09-01 Pmv Pharmaceuticals Inc Deuterium-converted compounds to restore mutant P53 activity
WO2023227080A1 (zh) * 2022-05-25 2023-11-30 百极弘烨(南通)医药科技有限公司 一种protac化合物、含其的药物组合物及其制备方法和应用
WO2023250431A2 (en) * 2022-06-22 2023-12-28 Children's Hospital Medical Center Multi-cyclic irak and flt3 inhibiting compounds and uses thereof
IL320191A (en) * 2022-10-12 2025-06-01 Maze Therapeutics Inc Solute carrier family 6A member 19 inhibitors (SLC6A19) and methods of using them
KR102827002B1 (ko) * 2023-06-28 2025-06-30 국립순천대학교산학협력단 신규한 마리노바자난 화합물 및 이를 포함하는 암 전이 및 침윤 억제, 또는 암 치료용 조성물

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4025510A (en) * 1975-12-01 1977-05-24 E. I. Du Pont De Nemours And Company 2,4-Diaryl[1,3,4H]thiadiazines fused to quinoxalines
US6090382A (en) 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
DE10022925A1 (de) * 2000-05-11 2001-11-15 Basf Ag Substituierte Indole als PARP-Inhibitoren
WO2003009852A1 (en) * 2001-07-24 2003-02-06 Merck & Co., Inc. Tyrosine kinase inhibitors
US7199119B2 (en) * 2002-10-31 2007-04-03 Amgen Inc. Antiinflammation agents
CA2534127A1 (en) 2003-07-31 2005-02-10 Boehringer Ingelheim Pharmaceuticals, Inc. Substituted benzothiophene compounds and uses thereof
GB0400895D0 (en) * 2004-01-15 2004-02-18 Smithkline Beecham Corp Chemical compounds
WO2005105809A1 (en) * 2004-05-04 2005-11-10 F. Hoffmann-La Roche Ag Thienopyridines as ikk inhibitors
EP1753764B1 (en) 2004-06-09 2008-10-29 Glaxo Group Limited Pyrrolopyridine derivatives
TW200626142A (en) * 2004-09-21 2006-08-01 Glaxo Group Ltd Chemical compounds
CN101189243A (zh) * 2005-04-06 2008-05-28 阿斯利康(瑞典)有限公司 取代的杂环及其作为chk1、pdk1和pak抑制剂的应用
US20090275570A1 (en) * 2005-04-06 2009-11-05 Astrazeneca Ab Substituted heterocycles and their use as chk1, pdk1 and pak inhibitors
US8063071B2 (en) * 2007-10-31 2011-11-22 GlaxoSmithKline, LLC Chemical compounds
MX2007016541A (es) * 2005-06-30 2008-03-07 Smithkline Beecham Corp Compuestos quimicos.
AU2007232297B2 (en) 2006-04-03 2012-09-20 Msd Italia S.R.L. Amide substituted indazole and benzotriazole derivatives as poly(ADP-ribose)polymerase (PARP) inhibitors
PE20081889A1 (es) * 2007-03-23 2009-03-05 Smithkline Beecham Corp Indol carboxamidas como inhibidores de ikk2
JP2010524950A (ja) * 2007-04-16 2010-07-22 セレネックス， インコーポレイテッド テトラヒドロインドールおよびテトラヒドロインダゾール誘導体
EP2144630A2 (en) * 2007-04-27 2010-01-20 AstraZeneca AB Chk1 inhibitors with b cell depleting antibodies for the treatment of hematologic malignancies
WO2008150490A2 (en) 2007-06-01 2008-12-11 Abbott Biotechnology Ltd. Uses and compositions for treatment of psoriasis and crohn's disease
CN101481380B (zh) * 2008-01-08 2012-10-17 浙江医药股份有限公司新昌制药厂 噻吩并哒嗪类化合物及其制备方法、药物组合物及其用途
AR070317A1 (es) 2008-02-06 2010-03-31 Osi Pharm Inc Furo (3,2-c) piridina y tieno (3,2-c) piridinas
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
US8084620B2 (en) * 2008-12-19 2011-12-27 Bristol-Myers Squibb Company Carbazole carboxamide compounds useful as kinase inhibitors
HUE043522T2 (hu) 2009-09-04 2019-08-28 Biogen Ma Inc Bruton tirozinkináz inhibitorok
US8772301B2 (en) 2009-12-18 2014-07-08 Sunovion Pharmaceuticals, Inc. Compounds for treating disorders mediated by metabotropic glutamate receptor 5, and methods of use thereof
US20110212461A1 (en) 2010-02-26 2011-09-01 Hans Marcus Ludwig Bitter Prediction of cardiotoxicity
CA2799904A1 (en) 2010-05-20 2011-11-24 F. Hoffmann-La Roche Ag Pyrrolo [2, 3 - b] pyrazine - 7 - carboxamide derivatives and their use as jak and syk inhibitors
EP2582668B1 (en) 2010-06-16 2016-01-13 Bristol-Myers Squibb Company Carboline carboxamide compounds useful as kinase inhibitors
US9050334B2 (en) 2010-07-16 2015-06-09 Innov88 Llc MIF inhibitors and their uses
BR112013006016A2 (pt) 2010-09-15 2016-06-07 Hoffmann La Roche compostos de azabenzotiazol, composições e métodos de uso
FR2969151B1 (fr) * 2010-12-17 2016-11-04 Oreal Derives du 4-amino et leur utilisation pour la coloration d'oxydation des fibres keratiniques.
EP2696682B1 (en) 2011-04-13 2018-03-21 Innovimmune Biotherapeutics, Inc. Mif inhibitors and their uses
EP2561759A1 (en) * 2011-08-26 2013-02-27 Bayer Cropscience AG Fluoroalkyl-substituted 2-amidobenzimidazoles and their effect on plant growth
WO2013148603A1 (en) 2012-03-27 2013-10-03 Takeda Pharmaceutical Company Limited Cinnoline derivatives as as btk inhibitors
CA2916298C (en) * 2013-06-26 2021-10-12 Abbvie Inc. Primary carboxamides as btk inhibitors

Also Published As

Publication number Publication date
LT3013337T (lt) 2019-01-10
JP2019123740A (ja) 2019-07-25
RU2016102137A3 (enExample) 2018-04-28
KR20160025580A (ko) 2016-03-08
AU2014302365A1 (en) 2015-12-24
CA2916298A1 (en) 2014-12-31
US20190284135A1 (en) 2019-09-19
CY1121146T1 (el) 2020-05-29
ME03307B (me) 2019-10-20
US20210179556A1 (en) 2021-06-17
RU2016102137A (ru) 2017-07-31
US20150005279A1 (en) 2015-01-01
JP6770127B2 (ja) 2020-10-14
HRP20190093T1 (hr) 2019-02-22
CN105530932B (zh) 2019-09-27
NZ714797A (en) 2021-06-25
SG11201510503UA (en) 2016-01-28
JP6509838B2 (ja) 2019-05-08
HK1224202A1 (en) 2017-08-18
BR112015032330A2 (pt) 2017-08-22
TWI642657B (zh) 2018-12-01
IL267101A (en) 2019-08-29
KR102273997B1 (ko) 2021-07-08
CN105530932A (zh) 2016-04-27
RU2708395C2 (ru) 2019-12-06
MX355943B (es) 2018-05-07
DK3013337T3 (en) 2019-02-25
BR112015032330B1 (pt) 2019-01-22
US20170174624A1 (en) 2017-06-22
TW201514145A (zh) 2015-04-16
ZA201509012B (en) 2020-05-27
MX2015017973A (es) 2016-05-10
SI3013337T1 (sl) 2019-02-28
EP3013337B1 (en) 2018-10-31
HUE040645T2 (hu) 2019-03-28
PL3013337T3 (pl) 2019-06-28
AU2014302365B2 (en) 2018-11-15
JP2021001212A (ja) 2021-01-07
AU2021201463A1 (en) 2021-03-25
EP3013337A1 (en) 2016-05-04
EP3013337A4 (en) 2016-12-28
IL243332A0 (en) 2016-02-29
ES2708998T3 (es) 2019-04-12
AU2019200901A1 (en) 2019-02-28
CA2916298C (en) 2021-10-12
UY35630A (es) 2015-01-30
IL243332B (en) 2019-06-30
PT3013337T (pt) 2019-02-05
JP2016523911A (ja) 2016-08-12
NZ754039A (en) 2021-06-25
EP3483167A1 (en) 2019-05-15
RS58273B1 (sr) 2019-03-29
EP4008328A1 (en) 2022-06-08
WO2014210255A1 (en) 2014-12-31
US9567339B2 (en) 2017-02-14

Similar Documents

Publication Publication Date Title
IL267101A (en) Primary carboxamides as btk inhibitors
IL279682A (en) Benzoquinolone compounds as VMAT2 inhibitors
EP3082809A4 (en) Btk inhibitors
EP3008633A4 (en) QUICK GROUPING OF TIME SERIES
ZA201506156B (en) Novel inhibitors
GB201304526D0 (en) New compounds
LT2943561T (lt) Foto bioreaktorius
GB201518344D0 (en) No details present
EP3082811A4 (en) Btk inhibitors
GB201304527D0 (en) New compounds
IL244617A0 (en) Benzoquinolone compounds as vmat2 inhibitors
IL240763B (en) The halopyrazoles as thrombin inhibitors
GB201322992D0 (en) New Process
GB201310928D0 (en) New Processes
GB201301346D0 (en) Well completion
GB201317756D0 (en) New process
GB201313211D0 (en) New process
GB201305503D0 (en) Inhibitor
GB201318565D0 (en) New processes
GB201300961D0 (en) New processes
GB201305945D0 (en) New compounds
GB201304777D0 (en) New compounds
GB201304773D0 (en) New compounds
GB201304780D0 (en) New compounds
GB201304782D0 (en) New compounds